| 前收市價 | 1.3500 |
| 開市 | 1.4000 |
| 買盤 | 0.0000 |
| 賣出價 | 4.8000 |
| 拍板 | 340.00 |
| 到期日 | 2024-10-18 |
| 今日波幅 | 1.3000 - 1.4000 |
| 合同範圍 | 無 |
| 成交量 | |
| 未平倉合約 | 31 |
Barrons.comReshma Kewalramani Is Guiding Vertex Pharmaceuticals to Its Next Big Thing
Under her predecessor, Vertex revolutionized the treatment of cystic fibrosis. Kewalramani’s job is to maintain that franchise while guiding Vertex to its next big thing. There are plenty of options: Vertex is developing a pain medicine called suzetrigine that could satisfy enormous demand for a nonopioid pain reliever, and a stem-cell-derived therapy called VX-880 that the company hopes will be a cure for Type 1 diabetes, among many programs.
Motley FoolForget Eli Lilly, Buy This Magnificent Biotech Stock Instead
Lilly is a good pick...but this one is better.
Insider MonkeyVertex Pharmaceuticals (NASDAQ:VRTX): The Best Healthcare Stock to Buy in 2024?
We recently published a list Analyst Recommends 10 Best Stocks to Diversify Your Portfolio Away from Mega-Cap Tech and AI Stocks. Since Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) ranks 7th on the list, it deserves a deeper look. Venu Krishna, Head of U.S. Equity Strategy & Global Equity Linked Strategies at Barclays, recently shared a basket of stocks […]
